This is a type of cancer that starts in the urinary tract. The urinary tract includes your kidneys, ureters, bladder, and urethra. It's a serious condition that needs medical attention.
Every report comes from a Lived member, sent anonymously.
Have you tried Keytruda (Pembrolizumab) for Urinary Tract Cancer?
Urinary tract cancer is an umbrella term for cancers that begin anywhere along the system that makes, stores and carries urine. That system runs from the kidneys, through the renal pelvis (the funnel at the center of each kidney where urine collects) and the ureters (the tubes leading to the bladder), to the bladder and finally the urethra, the tube that carries urine out of the body. Bladder cancer and kidney cancer are the most common of these. Cancers of the renal pelvis and ureter are less common, and cancer of the urethra is rare. These cancers share one key warning sign, blood in the urine, but they behave differently. Most bladder, ureter and renal pelvis cancers start in the urothelium, the stretchy lining that covers the inside of the urinary tract, and are called urothelial or transitional cell cancers. Because that lining is continuous, people who have had bladder cancer have a higher chance of later cancer in the ureter, renal pelvis or urethra. The most common adult kidney cancer, renal cell cancer, is different: it starts in the tiny tubes inside the kidney that filter blood, and it often causes no symptoms at first. Wilms tumor is a rare kidney cancer that mainly affects children. Prostate and testicular cancers are treated by the same specialists but are cancers of the reproductive organs rather than the urinary tract.
Smoking is the most important risk factor people can change. Chemicals from tobacco are absorbed into the blood, filtered out by the kidneys and concentrated in urine, so the lining of the bladder and upper urinary tract is exposed to them for long periods. Smoking raises the risk of bladder, kidney and upper tract cancers. Other contributors differ by organ. Bladder cancer becomes more likely with age and, in the United States, is more common in men than in women. Long-term workplace exposure to certain dyes, paints, metals, petroleum products, and chemicals used to make rubber, leather, textiles and plastics raises the risk of bladder and upper tract cancers. Past radiation to the pelvis, the chemotherapy drugs cyclophosphamide and ifosfamide, the Chinese herb Aristolochia fangchi, well water with high arsenic levels and long-term use of urinary catheters are also linked to bladder cancer. Kidney cancer is linked to excess body weight, high blood pressure, long-term misuse of some pain medicines (including over-the-counter ones) and inherited conditions such as von Hippel-Lindau disease. Urethral cancer is more likely after bladder cancer and with long-standing inflammation of the urethra, such as from human papillomavirus (HPV) infection or frequent urinary tract infections. These are risk factors rather than direct causes. Many people with several of them never develop cancer, and some people with none of them do.
Blood in the urine is the usual starting point. It may be visible, turning urine pink, red or brown, or found only on a urine test, and it can appear once and then not return for a while. Infections, stones, an enlarged prostate, hard exercise and some medicines can all cause it, so the purpose of testing is to find the source. A first visit usually includes a urine test to confirm blood and check for infection, a physical exam, and questions about smoking and work exposures. When cancer needs to be ruled out, two tests do most of the work. Cystoscopy is a look inside the urethra and bladder with a cystoscope, a thin tube with a light and lens; it shows growths on the bladder lining directly. A CT urogram is a computed tomography (CT) scan taken before and after contrast dye is injected into a vein, timed so the dye outlines the kidneys, ureters and bladder as it drains. A suspicious bladder growth is removed or sampled through the scope and examined under a microscope, which confirms the diagnosis and shows how deep it goes. Tumors higher up can be sampled with ureteroscopy, a thinner scope passed into the ureter and kidney, and urine can be checked for cancer cells. Kidney masses are often diagnosed from CT or MRI (magnetic resonance imaging) scans; a needle biopsy is used when the images alone do not answer the question. Staging then describes how far the cancer has grown. For bladder cancer the most important distinction is whether it has reached the muscle layer of the bladder wall. Non-muscle-invasive cancer is confined to the lining or the tissue just beneath it, while muscle-invasive cancer needs more extensive treatment. Grade, meaning how abnormal the cells look, also matters: high-grade cancers are more likely to grow deeper or spread.
Treatment depends on where the cancer started, how far it has grown, its grade and the person's overall health. Care is usually led by a urologist or urologic oncologist, often working with medical and radiation oncologists. Bladder cancer that has not reached the muscle is usually removed with a wire loop passed through a scope in the urethra, a procedure called transurethral resection. Because these cancers often come back, most people then have medicine placed directly into the bladder through a catheter: chemotherapy such as mitomycin or gemcitabine, or BCG (bacillus Calmette-Guérin), an immunotherapy that triggers an immune response against remaining cancer cells in the bladder lining. Higher-risk cancers may need BCG repeated for up to three years. This approach keeps the bladder but commits a person to regular treatments and checks. Muscle-invasive bladder cancer is treated either by removing the bladder (radical cystectomy) or with radiation combined with chemotherapy for people who cannot have or prefer not to have surgery. Chemotherapy that includes cisplatin, given before surgery, helps people live longer than surgery alone, and newer combinations of immunotherapy and targeted drugs are also used around surgery. When the bladder is removed, the surgeon creates another way to store and pass urine, such as an opening on the abdomen that drains into a bag or an internal pouch made from intestine. Kidney cancer that has not spread is usually treated with surgery. When possible, surgeons remove only the tumor and a rim of healthy tissue (partial nephrectomy) to preserve kidney function; otherwise the whole kidney is removed (radical nephrectomy). Small tumors can sometimes be destroyed with heat or freezing (ablation), and for some small kidney masses, active surveillance with regular scans and treatment only if the mass grows is a reasonable choice. Cancers of the renal pelvis and ureter are most often treated by removing the kidney, the ureter and a small cuff of bladder; a superficial tumor in the lowest part of the ureter can sometimes be removed on its own. When these cancers have spread, treatment uses medicines that travel through the body. Immunotherapy drugs such as pembrolizumab (Keytruda) help the immune system recognize cancer and are used for both urothelial and kidney cancer, often combined with a targeted drug. Enfortumab vedotin (Padcev) is an antibody that carries a chemotherapy drug directly to urothelial cancer cells. These treatments can control cancer in many people, but responses vary. Immunotherapy can inflame almost any organ, and enfortumab vedotin can cause skin reactions that are occasionally severe, so both need close monitoring. Clinical trials are an option at many stages.
Outlook depends mostly on which organ is involved and how far the cancer has grown when it is found. Non-muscle-invasive bladder cancer can often be cured, and most cancers of the renal pelvis and ureter can be cured when found early. Cancer that has spread beyond the urinary tract is much harder to treat, and care then focuses on controlling it and keeping symptoms manageable for as long as possible. Follow-up is a large part of life after diagnosis. Bladder cancer tends to come back, even when it was noninvasive at first, so people usually have repeat cystoscopies at regular intervals for years, sometimes with urine tests and imaging. Low-grade cancers mostly recur in the bladder lining, while high-grade cancers are more likely to invade deeper, which is one reason the follow-up schedule depends on the cancer's risk level. After kidney cancer treatment, periodic scans and blood tests look for recurrence and keep track of kidney function. A person can live normally with one working kidney, or even part of one. Some treatments change daily routines. After the bladder is removed, people learn to care for a stoma and urine bag, or to empty an internal pouch with a catheter. Adjusting takes time, but many people return to most of what they did before surgery, with help from specialist nurses and support groups. Surgery, radiation and chemotherapy can also affect sexual function and body image, which is worth raising with the care team because practical help is available.
See a clinician about any blood in the urine, even if it happened only once, caused no pain or has since cleared, and about blood found on a routine urine test. Also arrange a visit for pain in the side or back that does not go away, a lump in the abdomen, unexplained weight loss, or ongoing burning, urgency or frequent urination that is not explained by an infection. If you are being treated, contact your care team promptly about new symptoms during immunotherapy, such as diarrhea, cough, shortness of breath or a rash, since immune side effects are easier to treat when caught early. Get medical care right away if you are unable to pass urine, for example because blood clots are blocking the flow, or have severe pain in the lower abdomen; a bladder that cannot empty can become dangerous quickly.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Urinary Tract Cancer is like, what's helped you, or ask the community a question.